Lexicon Pharmaceuticals
Präsenz
Lexicon Pharmaceuticals ist einer der ...
Lexicon Pharmaceuticals ist ein Unternehmen, das unter dem Börsenticker LXRX (US) gelistet ist.
Führungskräfte
Siehe das Organigramm mit seine 30 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Lexicon Pharmaceuticals
- Lonnel Coats, President and Chief Executive Officer & Director (re...
- Raymond Debbane, Chairman of the Board
- Philippe Amouyal, Director
Letzte Veränderungen der Führungskräfte auf Lexicon Pharmaceuticals
- Lonnel Coats, President and Chief Executive Officer & Director, geht am 7 Juli. 2024 in den Ruhestand (Nachrichten veröffentlicht am 2, Mai 2024).
- Lisa Defrancesco wird vom Unternehmen als Head of Investor Relations and Corporate Strategy am 13 Nov.. 2023 eingestellt (Nachrichten veröffentlicht am 2, November 2023).
- Matthew Cullen, wurde beim Unternehmen als Vice President of Value and Access eingestellt (Nachrichten veröffentlicht am 2, November 2023).
Weitere Informationen zu den Änderungen auf Lexicon Pharmaceuticals
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Lexicon Pharmaceuticals nachzuverfolgen.
Biotechnologie
Lexicon Pharmaceuticals hat 2.286 Konkurrenten , einschließlich Lonza (Schweiz), Eurofins (Luxemburg) und Adaptive Phage Therapeutics (USA).
Popular M&A news in Biotechnologie
- Karius hat gerade eine Spendenaktion von 100 Millionen Dollar angekündigt. (veröffentlicht am 3, Mai 2024).
- Transcarent hat gerade eine Spendenaktion von 126 Millionen Dollar angekündigt. (veröffentlicht am 2, Mai 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (veröffentlicht am 2, Mai 2024).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach Lexicon Pharmaceuticals
- Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization | Lexicon Pharmaceuticals, Inc.Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable a
- New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses
- Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
- Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023 | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2,
- New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses of Sotagliflozin to Be Pre
- Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
- Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia | Lexicon Pharmaceuticals, Inc.Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
- Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Heal
- Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results from the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit | Lexicon Pharmaceuticals, Inc.Lexicon’s L
- Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
- View more press releases Close
Social media about Lexicon Pharmaceuticals
- Lexicon Pharmaceuticals auf Wikipedia, Google News & Yahoo Finance
- Lexicon Pharmaceuticals auf LinkedIn, Twitter & YouTube
In Kontakt kommen
Jetzt seine Führungskräfte, darunter auch Lonnel Coats, per E-Mail kontaktieren. 
Lexicon Pharmaceuticals unter +1 281... anrufen
